UNSPSC 51383512: Tenidap sodium

This classification denotes a nonsteroidal antiinflammatory drug with the molecular structure C14H8CLN2O3S.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, DCV1328NH2 chemically known as 1h-indole-1-carboxamide, 5-chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-, monosodium salt, (z)-, but more commonly known as tenidap sodium, which bears US NIH Compound Identifier 60711. European Medicines Agency schedules Tenidap sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04719MIG.

UNSPSC 51383512 Tenidap sodium is a Commodity code that nominally designates a specific anti-inflammatory pharmaceutical ingredient, but recent state and local opportunities tagged under this code reveal a disconnect: the actual procurement activity is not for tenidap sodium itself, but rather for naloxone (opioid reversal), multi-source generic pharmaceuticals and over-the-counter products, and direct-to-manufacturer pharmacy benefit program infrastructure. State and local buying under this code encompasses emergency-response medications (naloxone kits and drug deactivation systems), bulk pharmaceutical supply agreements serving health systems and government employee benefits programs, and exploratory purchasing vehicles for pharmacy program redesign. The issuing bodies are predominantly state health and human services agencies, county health departments, and multistate cooperative purchasing alliances; Seminole County, Florida and the Texas Health and Human Services Commission appear in the recent record, alongside the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which administers agreements serving multiple state and local jurisdictions including Oregon.

Recent activity clusters in Florida, Texas, and the upper Midwest. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery to its Community Health Building, due July 26, 2023 (note: posted date is 2026 but response deadline is 2023, indicating data inconsistency in the source). The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor intelligence on direct-to-manufacturer pharmacy prescription programs prior to formal competitive solicitation. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with proposals due March 26, 2026; this vehicle requires vendors to work through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and imposes a 3 percent administrative fee on all contract purchases.